{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:36Z","timestamp":1707524916310},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,20]]},"DOI":"10.7759\/cureus.35221","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:53:00Z","timestamp":1676911980000},"source":"Crossref","is-referenced-by-count":0,"title":["Atypical Seropositive Striated Muscle Antibody Myasthenia Gravis Presentation With Metastatic B1 Thymoma: A Rare Case"],"prefix":"10.7759","author":[{"given":"Johnny S","family":"Randhawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren S","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Abou-El-Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Herring","family":"Sovory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/7622.4013","article-title":"A study of clinical characteristicsof mediastinal mass","volume":"8","author":"Aroor AR","year":"2014","unstructured":"Aroor AR, Prakasha S R, Seshadri S, S T, Raghuraj U. A study of clinical characteristicsof mediastinal mass. J Clin Diagn Res. 2014, 8:77-80. 10.7860\/JCDR\/2014\/7622.4013","journal-title":"J Clin Diagn Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38878-z","article-title":"Genetic characterization of thymoma","volume":"9","author":"Yu L","year":"2019","unstructured":"Yu L, Ke J, Du X, Yu Z, Gao D. Genetic characterization of thymoma. Sci Rep. 2019, 9:2369. 10.1038\/s41598-019-38878-z","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/474512","article-title":"Thymoma in myasthenia gravis: from diagnosis to treatment","volume":"2011","author":"Romi F","year":"2011","unstructured":"Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis. 2011, 2011:474512. 10.4061\/2011\/474512","journal-title":"Autoimmune Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis K","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020, 11:212. 10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi F","year":"2000","unstructured":"Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol. 2000, 57:1596-600. 10.1001\/archneur.57.11.1596","journal-title":"Arch Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli MN","year":"2012","unstructured":"Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?. Expert Rev Clin Immunol. 2012, 8:427-38. 10.1586\/eci.12.34","journal-title":"Expert Rev Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-340","article-title":"Myasthenia gravis associated with invasive malignant thymoma: two case reports and a review of the literature","volume":"8","author":"Beydoun SR","year":"2014","unstructured":"Beydoun SR, Gong H, Ashikian N, Rison RA. Myasthenia gravis associated with invasive malignant thymoma: two case reports and a review of the literature. J Med Case Rep. 2014, 8:340. 10.1186\/1752-1947-8-340","journal-title":"J Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx A","year":"2010","unstructured":"Marx A, Willcox N, Leite MI, Chuang WY, Schalke B, Nix W, Str\u00f6bel P. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. 2010, 43:413-27. 10.3109\/08916930903555935","journal-title":"Autoimmunity"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.8.3698","article-title":"Titin: major myofibrillar components of striated muscle","volume":"76","author":"Wang K","year":"1979","unstructured":"Wang K, McClure J, Tu A. Titin: major myofibrillar components of striated muscle. Proc Natl Acad Sci U S A. 1979, 76:3698-702. 10.1073\/pnas.76.8.3698","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/08916939509001933","article-title":"Titin antibodies in patients with late onset myasthenia gravis: clinical correlations","volume":"20","author":"Skeie GO","year":"1995","unstructured":"Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity. 1995, 20:99-104. 10.3109\/08916939509001933","journal-title":"Autoimmunity"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-5728(02)00145-5","article-title":"Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules","volume":"128","author":"Romi F","year":"2002","unstructured":"Romi F, B\u00f8 L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. Journal of neuroimmunology. 2002, 128:82-89. 10.1016\/s0165-5728(02)00145-5","journal-title":"Journal of neuroimmunology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1997.0162","article-title":"Titin transcripts in thymomas","volume":"10","author":"Skeie GO","year":"1997","unstructured":"Skeie GO, Freiburg A, Kolmerer B, Labeit S, Aarli JA, Appiah-Boadu S, Gilhus NE. Titin transcripts in thymomas. J Autoimmun. 1997, 10:551-7. 10.1006\/jaut.1997.0162","journal-title":"J Autoimmun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto AM","year":"2001","unstructured":"Yamamoto AM, Gajdos P, Eymard B, et al.. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001, 58:885-90. 10.1001\/archneur.58.6.885","journal-title":"Arch Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.7.843","article-title":"Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis","volume":"57","author":"Mygland A","year":"1994","unstructured":"Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994, 57:843-6. 10.1136\/jnnp.57.7.843","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi F","year":"2007","unstructured":"Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol. 2007, 14:617-20. 10.1111\/j.1468-1331.2007.01785.x","journal-title":"Eur J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1993.1042","article-title":"IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma","volume":"6","author":"Mygland A","year":"1993","unstructured":"Mygland A, Tysnes OB, Aarli JA, Matre R, Gilhus NE. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. J Autoimmun. 1993, 6:507-15. 10.1006\/jaut.1993.1042","journal-title":"J Autoimmun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10294","article-title":"Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro","volume":"27","author":"Skeie GO","year":"2003","unstructured":"Skeie GO, Mygland A, Treves S, Gilhus NE, Aarli JA, Zorzato F. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve. 2003, 27:81-9. 10.1002\/mus.10294","journal-title":"Muscle Nerve"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-4598(199803)21:3<329::aid-mus6>3.0.co;2-c","article-title":"Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum","volume":"21","author":"Skeie GO","year":"1998","unstructured":"Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum. Muscle Nerve. 1998, 21:329-335. 10.1002\/(sici)1097-4598(199803)21:3&lt;329::aid-mus6&gt;3.0.co;2-c","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck FC","year":"2011","unstructured":"Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011, 6:S1710-6. 10.1097\/JTO.0b013e31821e8cff","journal-title":"J Thorac Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00131.x","article-title":"Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis","volume":"108","author":"Huang CS","year":"2003","unstructured":"Huang CS, Hsu HS, Kao KP, Huang MH, Huang BS. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand. 2003, 108:136-8. 10.1034\/j.1600-0404.2003.00131.x","journal-title":"Acta Neurol Scand"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz A","year":"2017","unstructured":"Alipour-Faz A, Shojaei M, Peyvandi H, Ramzi D, Oroei M, Ghadiri F, Peyvandi M. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 2017, 117:245-9. 10.1007\/s13760-016-0689-z","journal-title":"Acta Neurol Belg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx A","year":"2022","unstructured":"Marx A, Chan JK, Chalabreysse L, et al.. The 2021 WHO classification of tumors of the thymus and mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors?. J Thorac Oncol. 2022, 17:200-13. 10.1016\/j.jtho.2021.10.010","journal-title":"J Thorac Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2003.07.042","article-title":"WHO histologic classification is a prognostic indicator in thymoma","volume":"77","author":"Kondo K","year":"2004","unstructured":"Kondo K, Yoshizawa K, Tsuyuguchi M, et al.. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004, 77:1183-8. 10.1016\/j.athoracsur.2003.07.042","journal-title":"Ann Thorac Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/135927-atypical-seropositive-striated-muscle-antibody-myasthenia-gravis-presentation-with-metastatic-b1-thymoma-a-rare-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:58Z","timestamp":1707508378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/135927-atypical-seropositive-striated-muscle-antibody-myasthenia-gravis-presentation-with-metastatic-b1-thymoma-a-rare-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.35221","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}